CD276 and melanoma: B7 homolog 3 (B7-H3 or CD276) has emerged as an interesting target, exhibiting high expression across a spectrum of solid and hematological malignancies, including melanoma, ovarian, prostate, lung, pancreatic, breast, colorectal, and glioblastoma (GBM), with low to no expression in normal healthy tissues [4].